natgillin/translations-raw huggingface dataset:
The beneficial effects seen were considered modest, particularly in patients who also took statins, and were not considered to outweigh the increased risks of serious infections in patients treated with the medicine. 
Koristni učinki so bili ocenjeni kot skromni, še zlasti pri bolnikih, ki so jemali tudi statine, in se niso šteli za zadostne, da bi odtehtali povečano tveganje za resne okužbe pri bolnikih, ki so se zdravili s tem zdravilom.
IL-1 beta is part of the immune system (the body's natural defences) and is involved in the inflammatory processes associated with heart and blood vessels problems. 
IL-1β je del imunskega sistema (naravne obrambe telesa) in je udeleženo v vnetnih postopkih, povezanih s težavami s srcem in krvnimi žilami.
It was to be available as a solution for injection under the skin in pre-filled pens and pre-filled syringes. 
Na voljo naj bi bilo v obliki raztopine za injiciranje pod kožo v napolnjenih peresnikih in napolnjenih injekcijskih brizgah.
The main measure of effectiveness was the decrease in the number of serious events such as heart attack, stroke or death. 
Glavno merilo učinkovitosti je bilo zmanjšanje števila resnih dogodkov, kot so miokardni infarkt, srčna kap ali smrt.
Patients also took other medicines 
Prejemali so tudi druga
commonly used to prevent heart problems, such as statins. 
zdravila, ki se običajno uporabljajo za preprečevanje težav s srcem, na primer statine.
Patients were given canakinumab Novartis at different doses (50, 150 or 300 mg) or placebo (a dummy treatment) once every three months for up to six years. 
Bolniki so vsake tri mesece do največ šest let prejemali canakinumab Novartis v različnih odmerkih (50, 150 ali 300 mg) ali placebo (zdravilo brez učinkovine).
The CHMP also questioned the appropriateness of the measure chosen by the company to select patients and to monitor the effectiveness of canakinumab Novartis. 
Odbor CHMP je izrazil tudi dvom o učinkovitosti ukrepa, ki ga je družba izbrala za izbiro bolnikov in spremljanje učinkovitosti zdravila canakinumab Novartis.
The company informed the CHMP that, while an extension to the above-mentioned study will stop, other studies investigating canakinumab for the treatment of other conditions will continue as planned. 
Družba je odbor CHMP obvestila, da bo sicer ustavila podaljšanje omenjene študije, druge študije, v katerih proučujejo kanakinumab za zdravljenje drugih stanj, pa se bodo nadaljevale po načrtih.
Canakinumab Novartis was expected to be used to prevent serious events such as stroke, heart attack or death in patients who have already had a heart attack. 
Zdravilo canakinumab Novartis naj bi se uporabljalo za preprečevanje resnih dogodkov, kot so možganska kap, srčni napad ali smrt, pri bolnikih, ki so že doživeli srčni napad.
In particular, the CHMP was of the opinion that the data provided by the company was not robust enough to clearly demonstrate that canakinumab Novartis is effective in all patients who have had a heart attack. 
Odbor je zlasti menil, da podatki, ki jih je predložila družba, niso dovolj trdni, da bi jasno pokazali, da je zdravilo canakinumab Novartis učinkovito pri vseh bolnikih, ki so doživeli srčni napad.
On 4 December 2018, Novartis Europharm Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for canakinumab Novartis, for the prevention of serious events such as stroke, heart attack or death in patients who have had a heart attack. 
Družba Novartis Europharm Ltd. je 4. decembra 2018 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti svojo vlogo za dovoljenje za promet z zdravilom canakinumab Novartis, ki naj bi se uporabljalo za preprečevanje resnih dogodkov, kot so možganska kap, srčni napad ali smrt, pri bolnikih, ki so doživeli srčni napad.
The active substance in canakinumab Novartis, canakinumab, is a monoclonal antibody (a type of protein) which has been designed to recognise and attach to interleukin 1 (IL-1) beta. 
Učinkovina v zdravilu canakinumab Novartis, kanakinumab, je monoklonsko protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna beljakovino interlevkin-1β (IL-1β) in se veže nanjo.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it would not be possible for them to reply to the Agency's concerns within the agreed timeframe. 
Družba je v dopisu, s katerim je agencijo obvestila o umiku vloge, navedla, da v zahtevanem časovnem okviru ne bi mogla zagotoviti potrebnih podatkov o proizvodnji zdravila.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of canakinumab Novartis did not outweigh its risks. 
Zato je odbor CHMP ob umiku vloge menil, da koristi zdravila canakinumab Novartis ne odtehtajo z njim povezanih tveganj.
Canakinumab Novartis is a medicine that contains the active substance canakinumab. 
Canakinumab Novartis je zdravilo, ki vsebuje učinkovino kanakinumab.
Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had remaining concerns and was of the provisional opinion that canakinumab Novartis could not have been approved for the prevention of serious heart problems in patients who have already had a heart attack. 
Odbor CHMP je na podlagi pregleda podatkov in odgovorov družbe na sezname vprašanj, ki jih je zastavil, ob umiku vloge izrazil določene zadržke in je začasno menil, da zdravila canakinumab Novartis ni mogoče odobriti za preprečevanje resnih težav s srcem pri bolnikih, ki so že doživeli srčni napad.
By attaching to IL-1 beta, canakinumab blocks its activity and reduces inflammation. 
Kanakinumab z vezavo na IL-1β zavira njegovo delovanje in zmanjša vnetje.
What is canakinumab Novartis? 
Kaj je zdravilo canakinumab Novartis?
What was canakinumab Novartis expected to be used for? 
Za kaj naj bi se zdravilo canakinumab Novartis uporabljalo?
How does canakinumab Novartis work? 
Kako zdravilo canakinumab Novartis deluje?
EMA/215997/2006 EMEA/V/C/000098 
EMA/215997/2006 EMEA/V/A/000098
cefovecin 
Convenia cefovecina
Other information about Convenia: 
Druge informacije o zdravilu Convenia:
The European Commission granted a marketing authorisation valid throughout the European Union, for Convenia on 19 June 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Convenia, veljavno po vsej Evropski uniji, odobrila dne 19. junija 2006.
Depending on the infection concerned, the injection can be repeated if necessary (up to three times). 
V odvisnosti od dane okužbe je injiciranje mogoče po potrebi ponoviti (do trikrat).
Swelling of the face, lips or eyes, or any difficulty breathing are more serious symptoms and require urgent medical attention. 
Otekanje obraza, ustnic ali oči ali težave z dihanjem so resnejši simptomi, ki zahtevajo nujno medicinsko pomoč.
One injection lasts for up to 14 days. 
Ena injekcija učinkuje do 14 dni.
Treated animals should not be used for breeding for 12 weeks after the last injection of Convenia. 
Zdravljene živali se za razplod ne smejo uporabljati 12 tednov od zadnjega injiciranja zdravila Convenia.
Convenia should be handled with care and all the recommended precautions be taken to avoid exposure to the product. 
Z zdravilom Convenia je treba ravnati previdno in izvesti vse priporočene previdnostne ukrepe, da bi tako preprečili izpostavljenost izdelku.
Like other antibiotics, cefovecin is not effective against all types of bacteria. 
Podobno kot drugi antibiotiki tudi cefovecin ni učinkovit proti vsem vrstam bakterij.
Cephalosporin and penicillin antibiotics can cause allergies in humans, and sometimes these allergies can be very serious. 
Cefalosporinski ali penicilinski antibiotiki lahko pri ljudeh povzročijo alergije in včasih so te alergije lahko zelo resne.
What benefit has Convenia shown during the studies? 
Kakšne koristi je zdravilo Convenia izkazalo med raziskavami?
No side-effects have been reported with Convenia to date. 
Doslej niso v zvezi z uporabo zdravila Convenia poročali o nikakršnih stranskih učinkih.
In all studies, Convenia was as effective in curing the infection as the comparator antibiotic. 
V vseh raziskavah je bilo zdravilo Convenia pri zdravljenju okužb enako učinkovito kot primerjalni antibiotik.
What is the risk associated with Convenia? 
Kakšna tveganja so povezana z zdravilom Convenia?
Convenia should also not be used in dogs or cats of less than 8 weeks old, or in dogs or cats with severe kidney problems (renal dysfunction). 
Zdravila Convenia se tudi ne sme uporabljati pri psih ali mačkah, mlajših od 8 tednov, ali pri psih ali mačkah z resnimi ledvičnimi težavami (ledvično disfunkcijo).
All these cephalosporin antibiotics, including cefovecin, kill bacteria by disrupting the building of the bacterial cell walls, so the bacteria die and the infection is cured. 
Vsi ti cefalosporinski antibiotiki, vključno s cefovecinom, uničujejo bakterije tako, da motijo tvorbo celične stene bakterije, zaradi česar bakterija odmre in okužba je ozdravljena.
Convenia has the benefit of a long duration of activity. 
Prednost zdravila Convenia je v dolgotrajnem učinkovanju.
It would be dangerous to use Convenia in other animals such as guinea pigs and rabbits (it is not licensed for use in these species). 
Uporaba zdravila Convenia pri drugih živalih, kot so morski prašički in zajci, bi bila nevarna (zdravilo ni odobreno za uporabo pri teh vrstah).
The studies measured the rate at which the infections were cured. 
V okviru teh raziskav so merili stopnjo ozdravitve okužb.
Cefovecin differs from other similar cephalosporin antibiotics as it stays in the dog's or cat's body for a very long time after it has been injected. 
Cefovecin se od drugih podobnih cefalosporinskih antibiotikov razlikuje po tem, da ostane v telesu psa ali mačke še zelo dolgo po injiciranju.
It is generally given as a single injection, and the effect of the injection lasts for up to 14 days. 
V splošnem se daje v obliki posamične injekcije, njeno učinkovanje pa traja do 14 dni.
There are two vials in each pack of Convenia, one vial containing a powder, and one vial containing the diluent. 
Vsako pakiranje zdravila Convenia vsebuje dve viali, pri čemer vsebuje ena prašek in druga razredčilo.
If any symptoms occur after accidental exposure to Convenia, for example a skin rash, then the advice of a doctor should be sought immediately. 
V primeru, da se po nehoteni izpostavitvi zdravilu Convenia pojavi katerikoli simptom, npr. kožni izpuščaj, se nemudoma posvetujete z zdravnikom.
Data from laboratory studies with different bacteria showed that cefovecin was effective against the bacteria specified in the product information (SPC and package leaflet). 
Podatki iz laboratorijskih raziskav z različnimi bakterijami so pokazali, da je cefovecin učinkovit proti bakterijam, navedenim v informacijah o zdravilu (SPC in Navodilih za uporabo).
Why has Convenia been approved? 
Zakaj je bilo zdravilo Convenia odobreno?
However, it should not be used in dogs or cats which have shown an allergy to any cephalosporin or penicillin-type antibiotics. 
Vendar pa se zdravila ne sme uporabljati pri psih ali mačkah, ki so izkazali/e alergijo na kateregakoli izmed cefalosporinskih ali penicilinskih antibiotikov.
The powder is dissolved in the diluent before use to make up a solution for injection. 
Pred uporabo se prašek raztopi v raztopilu, s čimer dobimo raztopino za injiciranje.
As no studies have been made in breeding animals with Convenia and it has an exceptionally long duration in the body, Convenia should not be used in pregnant or lactating dogs or cats. 
Glede na to, da z zdravilom Convenia ni bila izvedena nobena raziskava pri živalih za razplod ter upoštevaje njegovo izredno dolgotrajno zadrževanje v telesu, se zdravilo Convenia ne sme uporabljati pri brejih psih ali mačkah oz. psih ali mačkah v času laktacije.
Anyone allergic to penicillins or cephalosporins should also avoid contact with litter used by dogs or cats treated with Convenia. 
Vsakdo, ki je alergičen na peniciline ali cefalosporine, se mora tudi izogibati stiku z ležiščem, ki ga uporablja pes ali mačka, zdravljena z zdravilom Convenia.
Convenia is used to treat infections caused by certain specific bacteria (see the SPC for further details). 
Zdravilo Convenia se uporablja za zdravljenje okužb, ki jih povzročajo določene specifične bakterije (nadaljnje podrobnosti najdete v SPC).
What is Convenia used for? 
Za kaj se zdravilo Convenia uporablja?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Convenia exceed the risks for the treatment of dogs and cats with certain specified skin, soft tissue and urinary tract infections and recommended that Convenia should be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je sklenil, da so koristi zdravila Convenia pri zdravljenju psov in mačk z določenimi navedenimi okužbami kože, mehkih tkiv in sečil večje od morebitnih tveganj, zato je priporočil, da se za zdravilo Convenia odobri dovoljenje za promet.
Convenia should therefore not be handled by anyone who is hypersensitive (allergic) to such antibiotics, or by anyone who has been advised not to work with them. 
Posledično z zdravilom Convenia ne sme rokovati oseba, ki je preobčutljiva (alergična) na take antibiotike ali kateri je bilo rokovanje z antibiotiki odsvetovano.
The active substance in Convenia is cefovecin which belongs to a class of antibiotics called third generation cephalosporins. 
Zdravilna učinkovina, ki jo vsebuje zdravilo Convenia, je cefovecin, ki sodi v razred antibiotikov, imenovanih cefalosporini tretje generacije.
How has Convenia been studied? 
Kako je bilo zdravilo Convenia raziskano?
Convenia is used in cats to treat skin and soft tissue infections, such as wounds and abscesses. 
Zdravilo Convenia se uporablja pri mačkah za zdravljenje okužb kože in mehkih tkiv, kot so rane in ognojki.
It is also used in dogs to treat urinary tract infections caused by certain specific bacteria. 
Pri psih se uporablja tudi za zdravljenje okužb sečil, ki jih povzročajo določene specifične bakterije.
It is also used in cats to treat urinary tract infections caused by certain specific bacteria. 
Pri mačkah se uporablja tudi za zdravljenje okužb sečil, ki jih povzročajo določene specifične bakterije.
Convenia is used in dogs to treat skin and soft tissue infections; these are infections on the skin and in the layers just below the skin, such as wounds, abscesses and pyoderma (a skin infection with a rash and pustules). 
Zdravilo Convenia se uporablja pri psih za zdravljenje okužb kože in mehkih tkiv; to so okužbe na koži in v podkožnem tkivu, kot so rane, ognojki in piodermija (kožna okužba z izpuščaji in gnojnimi mehurčki (pustule)).
Convenia has also been studied in cats with skin and soft tissue infections (where it was compared to another antibiotic containing amoxicillin and clavulanic acid), and in a small study in cats with urinary tract infections, where it was compared with cefalexin. 
Zdravilo Convenia so preučevali tudi na mačkah z okužbami kože in mehkih tkiv (pri čemer so ga primerjali z drugim antibiotikom, vsebujočim amoksicilin in klavulansko kislino) ter v okviru majhne raziskave z mačkami z okužbami sečil, pri čemer so ga primerjali z cefaleksinom.
How does Convenia work? 
Kako zdravilo Convenia deluje?
Convenia has been studied in dogs with skin and soft tissue infections (where it was compared to another antibiotic containing amoxicillin and clavulanic acid) and in dogs with urinary tract infections (where it was compared to another cephalosporin antibiotic, cefalexin). 
Zdravilo Convenia so preučevali na psih z okužbami kože in mehkih tkiv (pri čemer so ga primerjali z drugim antibiotikom, vsebujočim amoksicilin in klavulansko kislino) ter na psih z okužbami sečil (pri čemer so ga primerjali z drugim cefalosporinskim antibiotikom cefaleksinom).
Convenia contains cefovecin, an antibiotic which is given by injection (under the skin). 
antibiotik, ki se daje z injekcijo (pod kožo).
What is Convenia? 
Kaj je zdravilo Convenia?
2.5 micrograms conjugated to tetanus toxoid as a carrier adsorbed on aluminium hydroxide hydrated Total: 0.26 milligrams Al3+ ** adsorbed on aluminium phosphate Total: 0.40 milligrams Al *** produced in Saccharomyces cerevisiae cells by recombinant DNA technology 
5 - 10 mikrogramov adsorbiran na aluminijev hidroksid Skupno: 0.26 milligrama Al ** adsorbiran na aluminijev fosfat *** 3pridobljen s tehnologijo rekombinantne DNA na celični kulturi Saccharomyces cerevisiae
Tetanus toxoid* 
Tetanusni toksoid*
Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 2 
Rekombinantni površinski antigen virusa hepatitisa B** (S protein)*** 10 mikrogramov Polisaharid bakterije Haemophilus influenzae tipa b (poliribozilribitol fosfat)
Inactivated Bordetella pertussis strain** Hepatitis B virus surface antigen recombinant** (S protein)*** 
Inakivirana bakterija Bordetella pertussis**
Invented nam Strength Pharmaceutical 
konjugiran na tetanusni toksoid kot nosilec
--1 ≥ 50x106 CD54+ cells/250mL 
--1 ≥ 50x106 CD54+ celic/250 ml
dispersion for infusion Intravenous use Bag 
Intravenska uporaba
Strength Pharmaceutical Form Route of Administration 
(Izmišljeno) ime Jakost Farmacevtska oblika Pot uporabe Stična ovojnina Vsebina (koncentracija)
When getting up, do so as slowly as possible. 
Ko boste vstali, to storite kar se da počasi.
A risk to the newborn/infants cannot be excluded. 
Tveganja za novorojenčke/dojenčke ni mogoče izključiti.
1Based on GSS. 
1Na podlagi GSS.
Repeat steps 3 to 7 in the same way until the whole dose has been taken. 
Na enak način ponavljajte korake od 3 do 7, dokler ni uporabljen celotni odmerek.
Wait for the next dose at its regular time. 
Počakajte na naslednji odmerek ob običajnem času.
Your liver function may need to be closely monitored. 
Morda bo treba delovanje vaših jeter skrbno spremljati.
Difference1 (Confidence Interval2) 
Razlika1 (interval zaupanja2)
• telaprevir and boceprevir. 
• telaprevir in boceprevir.
This is due to a sudden fall in blood pressure. 
To je posledica nenadnega znižanja krvnega tlaka.
See the diagram and instructions at the end of this section for how to measure and take (or give) a dose of medicine. 
Glejte diagram in navodila na koncu tega poglavja, da boste vedeli, kako odmeriti in vzeti (ali dati) odmerek tega zdravila.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART. 
Ponavadi so takšne reakcije opažali v prvih nekaj tednih ali mesecih po začetku KPRT.
Data to support these doses are lacking. 
Podatkov v podporo tem odmerkom ni.
Talk to your doctor about how to avoid infecting other people. 
Posvetujte se z zdravnikom, kako preprečiti okužbo drugih ljudi.
Total bilirubin 
Celotni bilirubin
Potential effect on immunity 
Potencialni vpliv na imunost
This dose adjustment has not been studied in HIV patients. 
Ta prilagoditev odmerka ni raziskana pri bolnikih s HIV.
This should be taken into consideration when treating infections such as active tuberculosis and invasive fungal infections. 
To je treba upoštevati pri zdravljenju okužb, kot so aktivna tuberkuloza in invazivne glivične okužbe.
The MOTIVATE studies were extended beyond 96 weeks, with an observational phase extended to 5 years in order to assess the long term safety of maraviroc. 
Študije MOTIVATE so bile podaljšane po 96 tednih z opazovalno fazo do 5 let, da bi ocenili dolgoročno varnost maraviroka.
After first opening: 60 days 
Po prvem odprtju: 60 dni.
Skin and liver reactions can occur as single events, or in combination. 
Kožne in jetrne reakcije se lahko pojavijo kot same ali v kombinaciji.
Therefore there is a need to start therapy shortly after a tropism test. 
Zdravljenje je torej treba začeti v kratkem času po testu tropizma.
If it is almost time for the next dose, do not take or give the missed dose. 
Če pa je že skoraj čas za naslednji odmerek, ne vzemite ali dajte pozabljenega odmerka.
• feeling very tired 
• občutek hude utrujenosti,
Pull out applicator plunger (D) until the applicator contains the first part of the full dose. 
Izvlecite bat aplikatorja (D), dokler aplikator ne vsebuje prvega dela celotnega odmerka.
The volume of distribution of maraviroc is approximately 194 L. 
Volumen porazdelitve maraviroka je približno 194 litrov.
This is particularly important if you are also taking some other medicines (see ‘Other medicines and CELSENTRI' later in section 2). 
To je še posebej pomembno, če jemljete nekatera druga zdravila (glejte "Druga zdravila in zdravilo CELSENTRI" v nadaljevanju v poglavju 2).
Get medical help immediately if you get these symptoms. 
Nemudoma poiščite zdravniško pomoč, če se pojavijo ti simptomi.
ULN: Upper Limit of Normal 
ZNM: zgornja normalna meja
Maraviroc should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus. 
Maravirok je med nosečnostjo dovoljeno uporabiti le v primeru, da pričakovane koristi upravičujejo možno tveganje za plod.
The population was 52% female and 69% black, with mean age of 10 years (range: 2 years to 17 years). 
V populaciji je bilo 52 % deklic in 69 % črncev; povprečna starost je bila 10 let (razpon: od 2 do 17 let).
It is not known how common this condition is. 
Pogostnost tega stanja ni znana.
The frequency of this is unknown (see section 4.4). 
Pogostnost le-teh je neznana (glejte poglavje 4.4).
Always take the dose recommended by your doctor. 
Vedno vzemite odmerek, ki vam ga je predpisal zdravnik.
Virologic Escape 
Virološki pobeg
Do not push too hard and squirt the liquid into the back of the throat, as that could cause choking. 
Ne potisnite premočno in ne brizgnite tekočine v zadnji del žrela, ker to lahko sproži dušenje.
Maraviroc may have a minor influence on the ability to drive and use machines. 
Maravirok ima lahko manjši vpliv na sposobnost vožnje in upravljanja strojev.
(See also ‘Liver problems' in section 4). 
(Glejte tudi "Težave z jetri" v poglavju 4.)
For example, if the dose is 15 ml, you need one and a half applicator -full of medicine. 
Če je na primer odmerek 15 ml, boste potrebovali enega ina pol polnega aplikatorja zdravila.
CELSENTRI can be taken with or without food. 
Zdravilo CELSENTRI je mogoče jemati s hrano ali brez nje.
CCR5 antagonists could potentially impair the immune response to certain infections. 
Antagonisti CCR5 lahko potencialno oslabijo imunski odziv na določene okužbe.
Remove the bottle cap (A). 
Odstranite pokrovček plastenke (A).
Caution should be exercised when treating these patients. 
Pri zdravljenju teh bolnikov je potrebna previdnost.
Push the plastic adapter (B) into the neck of the bottle so it is fully inserted. 
Potisnite plastični nastavek (B) v vrat plastenke, tako da je v celoti vstavljen.
Recommendations concerning coadministration in adults 
Priporočila glede sočasne uporabe pri odraslih
Date of first authorisation: 18th September 2007 Date of latest renewal: 20 July 2012 
Datum zadnjega podaljšanja: 20. julij 2012
When they start treatment, the immune system becomes stronger, so the body starts to fight infections. 
Ko začnejo zdravljenje, se imunski sistem lahko okrepi in telo se začne boriti z okužbami.
Alanine aminotransferase 
Alanin-aminotransferaza
Tell your doctor if you notice anything unusual about your own health or your child's health. 
Zdravniku morate povedati, če opazite karkoli nenavadnega v zvezi s svojim ali otrokovim zdravstvenim stanjem.
Remove the applicator from the adapter. 
Odstranite aplikator iz nastavka.
CELSENTRI could potentially increase your risk of developing infections. 
Zdravilo CELSENTRI lahko poveča tveganje za razvoj okužb.
Traditional IC50/IC90 fold-change was not a useful parameter to measure phenotypic resistance, as those values were sometimes unchanged despite significantly reduced sensitivity. 
Tradicionalna IZ50/IZ90-kratna sprememba ni bila uporabna za merjenje fenotipske odpornosti, ker so bile te vrednosti včasih nespremenjene kljub bistveno zmanjšani občutljivosti.